Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase 1 Trial of Lonsurf with Irinotecan and Bevacizumab in Patients with Unresectable Metastatic Colorectal Cancer(mCRC).

ABSTRACT: Interventions: 1 cycle is 28days. Lonsurf(25mg/m2)is administered orally twice daily in 1-5days and 8-12 days. Irinotecan(100mg/m2) and Bevacizumab(5mg/kg) is administered by injection in day 1 and day15. Primary outcome(s): Recommended dose:RD Study Design: Single arm Non-randomized

DISEASE(S): Advanced Colorectal Cancer

PROVIDER: 2634299 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase 1 Trial of Lonsurf with Irinotecan and Bevacizumab

Project description:Interventions: 1 cycle is 28days. Lonsurf(25mg/m2)is administered orally twice daily in 1-5days and 8-12 days. Irinotecan(100mg/m2) and Bevacizumab(5mg/kg) is administered by injection in day 1 and day15. Primary outcome(s): Recommended dose:RD Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2615622 | ecrin-mdr-crc

Phase 2 trial of TAS-102 plus bevacizumab in patients with advanced/recurrent colorectal cancer who had previously received on oxaliplatin, irinotecan and fluoropyrimidine

Project description:Interventions: TAS-102(35mg/m2) is administered orally twice daily in 1-5days and 15-20 days and Bevacizumab(5mg/kg) is administered by injection in day 1 and day15. 1 cycle is 28days. Primary outcome(s): Disease control rate Study Design: Single arm Non-randomized

| 2641267 | ecrin-mdr-crc

TAS-102 and Bevacizumab as salvage line chemotherapy for colorectal cancer

Project description:Interventions: TAS-102(35mg/m2) is administered orally twice daily in 1-5days and 15-20 days and Bevacizumab(5mg/kg) is administered by injection in day 1 and day15. 1 cycle is 28days. Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2646936 | ecrin-mdr-crc

Multicenter Phase 1b/2 Trial of TAS-102 with Bevacizumab in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.

Project description:Interventions: 1 cycle is 28days. TAS-102(35mg/m2) is administered orally twice daily in 1-5days and 8-12 days and Bevacizumab(5mg/kg) is administered by injection in day 1 and day15. Primary outcome(s): 4 month progression free survival by central assessment( 4M PFS) Study Design: Single arm Non-randomized

| 2628236 | ecrin-mdr-crc

A phase I/II study of Lonsurf combined with Oxaliplatin in metastatic colorectal cancer patients refractory to standard chemotherapy.

Project description:Interventions: Lonsurf/L-OHP therapy Lonsurf: 70mg/m2, d1-5, d15-19 (fixed dose) L-OHP: 50-85mg/m2, d1,d15 (dose escalation) every 4 weeks Primary outcome(s): [Phase I part] To determine recommended dose (RD) and maximum tolerated dose (MTD) [Phase II part]Disease Control Rate (DCR) Study Design: Single arm Non-randomized

| 2631090 | ecrin-mdr-crc

Multicenter Phase 1b/2 Trial of Nintedanib with TAS-102 in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies.

Project description:Interventions: 1 cycle is 28days. Nintedanib (150mg or 200mg) is orally administered twice daily and TAS-102 (35mg/m2) is orally administered twice daily in 1-5days and 8-12 days Primary outcome(s): 16 weeks progression free survival rate ( 16W PFS rate) Study Design: Single arm Non-randomized

| 2632430 | ecrin-mdr-crc

Use-results survey for Lonsurf combination tablet T15 & Lonsurf combination tablet T20

Project description:Intervention name : Lonsurf combination tablet T15/T20 INN of the intervention : trifluridine + tipiracil hydrochloride Dosage And administration of the intervention : Usually, the standard doses below are defined as the initial dose (single dose) for adults according to body surface area (approximately 35 mg of Trifluridine/m2/dose). Lonsurf is administered twice daily, after breakfast and after the evening meal, for 5 consecutive days, followed by a 2-day rest. After repeating this twice, follows a 14-day rest. This is one cycle of the regimen and it shall be repeated. Study Design: Postmarketing surveillance

| 2611187 | ecrin-mdr-crc

Use-results survey for Lonsurf combination tablet T15 & Lonsurf combination tablet T20

Project description:Interventions: investigational material(s) Generic name etc : Lonsurf combination tablet T15/T20 INN of investigational material : trifluridine + tipiracil hydrochloride Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Usually, the standard doses below are defined as the initial dose (single dose) for adults according to body surface area (approximately 35 mg of Trifluridine/m2/dose). Lonsurf is administered twice daily, after breakfast and after the evening meal, for 5 consecutive days, followed by a 2-day rest. After repeating this twice, follows a 14-day rest. This is one cycle of the regimen and it shall be repeated. Study Design: Postmarketing surveillance

| 97953 | ecrin-mdr-crc

Effect of lipoprotein(a) on Arterial Endothelial Cells

Project description:Human Arterial Endothelial Cells (HAECs; Lonza) were incubated with either 5mg/dl or 100mg/dl isolated lipoprotein(a) for 6 hours. Next, RNA was isolated (RIN>9) and processed for NGS. NGS details: Sequencing of RNA (rRNA depleted), HiSeq4000, Paired-End, 150 bp

2020-05-26 | GSE145898 | GEO

A randomized clinical trial of adjuvant chemotherapy with TS-1 versus UFT following curative operation for Stage III colorectal cancer

Project description:Interventions: UFT 400mg/m2/day 5days’ medication, 2days’ rest Start medication within 6weeks postoperatively, continue for 12months TS-1 80mg/m2/day 28days’ medication, 14days’ break Start medication within 6weeks postoperatively, continue for 12months Primary outcome(s): 3-year disease free survival Study Design: Parallel Randomized

| 2609743 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data